Keyword: Germany

Royal Philips signed two long-term consultancy deals in Germany to supply equipment and reform workflows as it transitions to a solutions provider.

Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity.

Researchers in Germany pinpointed why targeting Notch and MAPK signaling individually may actually exacerbate colon cancer.

Sanofi will license out a host of infectious disease assets to Evotec, with 100 staffers also moving into its R&D engine.

Magenta could pay the German biotech up to $334 million in milestones if the antibody drug conjugate pacts hit their targets.

Medigene has been given a green light in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program.

The German company is seeking $22 million to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer.

Boehringer Ingelheim is deepening its venture fund pockets from €100 million to €250 million as it looks to change up its investment strategy.

Bayer has signed a potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal for the German pharma in the past week.

Germany’s Evotec has penned another deal amid a stream of R&D pacts over the past year, this time with PARP player Tesaro.